Key terms

About XGN

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest XGN news

May 14 7:37am ET Exagen price target raised to $7 from $5 at Cantor Fitzgerald May 14 7:36am ET Exagen’s Strong Q1 Earnings and Growth Potential Justify Buy Rating May 14 7:21am ET Cantor Fitzgerald Sticks to Their Buy Rating for Exagen (XGN) May 13 7:05pm ET Buy Rating Affirmed for Exagen Amid Strong Sales Growth and Promising Outlook May 13 6:55pm ET Exagen Outperforms: A Strong Buy on Rising Revenues, Margins, and Innovative Growth Prospects May 13 8:04am ET Exagen sees FY24 revenue at least $55M, consensus $54.16M May 13 8:04am ET Exagen reports Q1 EPS (19c), consensus (36c) Apr 26 8:42am ET Exagen Inc Board Reshuffle and New Class I Director Appointment Apr 26 8:39am ET Exagen to reduce size of board to seven from nine Apr 09 7:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Mar 20 5:56am ET Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives Mar 19 2:00am ET Exagen’s Challenge: Strengthening Financial Controls to Restore Confidence and Secure Growth Mar 18 7:05pm ET Exagen’s Strong Q4 Performance and Positive Outlook Justify Buy Rating Mar 18 1:49pm ET Exagen continues to execute on re-acceleration strategy, says Canaccord Mar 18 8:03am ET Exagen sees FY24 revenue $54M, consensus $54.13M Mar 18 8:02am ET Exagen reports Q4 EPS (31c), consensus (43c)

No recent press releases are available for XGN

XGN Financials

1-year income & revenue

Key terms

XGN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

XGN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms